Search

Displaying results 3661 - 3670 of 10000 in total
  1. Drug

    NNZ-2591

    go.drugbank.com/drugs/DB15601
    Investigational

    [L11100] Clinical trials are expected to begin in 2020.[L11103,L11100] … It was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019.

  2. Drug

    Tapinarof

    go.drugbank.com/drugs/DB06083
    ApprovedInvestigational

    [A248790] Tapinarof received initial approval from the FDA in 2022.[L41845] … Tapinarof is a novel, first-in-class, small-molecule AhR agonist that is indicated for the treatment of adult psoriasis.

  3. Drug

    Autologous cultured chondrocytes

    go.drugbank.com/drugs/DB10997
    ApprovedInvestigational

    It has been used since 1995 as Carticel and gained biologic license in 1997. The surgical implantation was first performed in Sweden. … Autologous cultured chrondrocytes are used as autologous cell therapy to repair articular cartilage injuries in the knee (femoral condyle) due to acute or repetitive trauma.

  4. Drug

    Sotrovimab

    go.drugbank.com/drugs/DB16355
    ApprovedInvestigational

    found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting. … [L41369] Sotrovimab was granted marketing authorization in the European Union in December 2021 under the brand name Xevudy.[L39625,L39620]

  5. Drug

    Penicillium camemberti

    go.drugbank.com/drugs/DB10809
    Approved

    Penicillium camemberti extract is used in allergenic testing.

    Mixtures: Number Ten Mold Mixture, Number Ten Mold Mixture
  6. Drug

    Penicillium roqueforti

    go.drugbank.com/drugs/DB10812
    Approved

    Penicillium roqueforti extract is used in allergenic testing.

    Mixtures: Number Ten Mold Mixture, Number Ten Mold Mixture
  7. Drug

    Influenza A virus A/Guangdong-Maonan/SWL1536/2019 CNIC-1909 (H1N1) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB15714
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: Flulaval Quadrivalent 2020/2021
  8. Drug

    MM-111

    go.drugbank.com/drugs/DB17983
    Investigational

    MM-111 is a novel bispecific antibody fusion protein that co-targets the the epidermal growth factor family receptor tyrosine kinases, ERBB2 and ERBB3.

  9. Drug

    Nedaplatin

    go.drugbank.com/drugs/DB13145
    ApprovedInvestigational

    It was approved for use in Japan in 1995.

  10. Drug

    Crotalus scutulatus antivenin

    go.drugbank.com/drugs/DB13891
    Approved

    Since it was approved by the Food and Drug Administration in October 2000, crotalidae poyvalent immune Fab (CroFab) has largely replaced previously used crotaline antivenom. … Specimens with type A venom, which cause a different pattern of injury than other rattlesnakes, have been reported in southern California, Nevada, Utah, Arizona, Texas, and New Mexico [L2856].